Смертельно опасные лекарства и организованная преступность

19. Roehr B. Health care in US ranks lowest among developed countries, Commonwealth Fund study shows. BMJ. 2008; 337: a889.

20. Starfield B., Shi L., Grover A., et al. The effects of specialist supply on populations’ health: assessing the evidence. Health Aff (Millwood). 2001 March 15. DOI: 10.1377/hlthaff.w5.97.

21. World Health Organization. The World Medicines Situation. Available online at: http://apps.who.int/medicinedocs/en/d/Js6160e/6.html#Js6160e6. (accessed 6 February 2013).

22. Wealth but not health in the USA. Lancet. 2013; 381: 177.

23. Nolte E., McKee C. M. Measuring the health of nations: updating an earlier analysis. Health Aff (Millwood). 2008; 27: 58–71.

24. Avendano M., Glymour M. M., Banks J., et al. Health disadvantage in US adults aged 50 to 74 years: a comparison of the health of rich and poor Americans with that of Europeans. Am J Public Health. 2009; 99: 540–8.

25. Jachuck S. J., Brierley H., Jachuck S., et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract. 1982; 32: 103–5.

26. Krogsbøll L. T., Jørgensen K. J., Grønhøj Larsen C., et al. General health checks for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2012; 10: CD009009.

27. Johnston M. E., Gibson E. S., Terry C. W., et al. Effects of labelling on income, work and social function among hypertensive employees. J Chronic Dis. 1984; 37: 417–23.

28. Butt D. A., Mamdani M., Austin P. C., et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012; 172: 1739–44.

29. Abramson J. Overdo$ed America. New York: HarperCollins; 2004.

30. Oliver M. Let’s not turn elderly people into patients. BMJ. 2009; 338: b873.

31. Cacciotti J., Clinton P. Pharm Exec 50: growth from the bottom up. Pharmaceutical Executive. 2012 May 1. Available online at: www.pharmexec.com/pharmexec/Noteworthy/Pharm-Exec-50-Growth-from-the-Bottom-Up/ArticleStandard/Article/detail/773562 (accessed 17 July 2013).

32. Berwick D. M., Hackbarth, A. Eliminating waste in US health care. JAMA. 2012; 307: 1513–16.

33. Liberati A., Magrini N. Information from drug companies and opinion leaders. BMJ. 2003; 326: 1156–7.

34. Tanne J. H. US healthcare executives hit pay jackpot. BMJ. 2011; 343: d8330.

35. Whelton R. S. Effects of Excessive CEO Pay on U. S. Society. Available online at: www.svsu.edu/emplibrary/Whelton%20article.pdf (accessed 6 November 2007).

36. Schafer A. Biomedical confl icts of interest: a defence of the sequestration thesis – learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8–24.

37. Relman A. A Second Opinion: rescuing America’s health care. New York: Public Affairs; 2007.

38. Krimsky S. Science in the Private Interest: has the lure of profits corrupted biomedical research? Lanham: Rowman & Littlefield; 2003.

39. Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.

40. Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2005.

41. Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995.

42. Day M. MRC says it will invent, develop, and market its own drugs. BMJ. 2007; 334: 1025.

43. Bloemen S., Hammerstein D. Time for the EU to lead on innovation. Health Action International Europe and Trans Atlantic Consumer Dialogue. 2012 April.

44. Bassand J.-P., Martin J., Rydén L., et al. The need for resources for clinical research: The European Society of Cardiology calls for European, international collaboration. Lancet. 2002; 360: 1866–9.

45. Gøtzsche P. C., Hansen M., Stoltenberg M., et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol. 1996; 25: 194–9.

46. Relman A. S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.

47. Gøtzsche P. C. Blinding during data analysis and writing of manuscripts. Controlled Clin Trials. 1996; 17: 285–90.

48. Borst-Eilers E. Assessing hospital technology in the Netherlands: new treatments are paid for only if they are part of an evaluation. BMJ. 1993; 306: 226.

49. Garattini S., Bertele V. How can we regulate medicines better? BMJ. 2007; 335: 803–5.